Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma
Sponsor: |
Concordia Laboratories Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ8209 |
U.S. Govt. ID: |
NCT02082522 |
Contact: |
Francis Gress: 646-317-0492 / fgg2109@columbia.edu |
The study aims to assess the effect of porfimer sodium with PDT administered with medical standard ofcare compared to medical standard of care alone on the overall survival time of patients with bile duct cancer and its effect on cholestasis (blocked bile flow), time-to-treatment failure, performance status, and health-related quality of life.
This study is closed
Investigator
Francis Gress, MD
Have you been diagnosed with inoperable advanced bile duct cancer? |
Yes |
No |